Cell Signaling Technology Logo - Extra Large
1% for the planet logo
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Fatty Acid Synthase (C20G5) Rabbit mAb (InTraSeq 3' Conjugate 3090) #15524

Filter:
  • SCA

    Product Specifications

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Rabbit IgG
    Application Key:
    • SCA-Single Cell Analysis 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Storage

    Supplied in PBS (pH 7.2), 2 mM EDTA, 0.05% Triton X-100, 2 mg/mL BSA, and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Fatty Acid Synthase (C20G5) Rabbit mAb (InTraSeq™ 3' Conjugate 3090) detects endogenous levels of total fatty acid synthase protein.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing rabbits with a synthetic peptide around Gly46 corresponding to the sequence of human fatty acid synthase.

    Background

    Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1).

    According to the research literature, increased expression of FASN has emerged as a phenotype common to most human carcinomas. For example, in breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Research studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    10x Genomics, 10x, Feature Barcode, and Chromium are the trademarks or registered trademarks of 10x Genomics, Inc.
    InTraSeq is a trademark of Cell Signaling Technology, Inc.
    Subject to patents licensed from 10x Genomics, Inc. for use with single-cell (i.e., Chromium) 10x products.
    U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.